Netherlands · Delayed Price · Currency is EUR Pharming Group Earnings Call Transcripts
Fiscal Year 2026
-
The company reported strong 2025 revenue growth and set 2026 guidance for continued expansion, driven by RUCONEST and Joenja. Key pipeline milestones include phase II readouts for Joenja in higher prevalent PIDs and pivotal data for napazimone, supporting a strategy to scale in rare diseases.
-
Strong 2025 sales growth was driven by RUCONEST and Joenja, with continued expansion of the rare disease pipeline. Financial guidance for 2026 projects 8–13% revenue growth, supported by disciplined cost management and increased R&D investment.
-
2025 saw 27% revenue growth, with 2026 guidance of $405–$425 million and increased R&D investment. Key pipeline programs leniolisib and napazimone are advancing, with pivotal data readouts expected in the next 18 months, targeting significant unmet needs in rare diseases.
Fiscal Year 2025
-
2025 saw 27% revenue growth, a return to operating profitability, and strong cash flow, driven by robust RUCONEST and Joenja performance. 2026 guidance anticipates 8–13% revenue growth, with Joenja's U.S. market as the main growth driver and continued disciplined capital allocation.
-
The company is experiencing strong growth from its two main assets, RUCONEST and Joenja, with strategic focus on high-value pipeline expansion and disciplined capital allocation. Recent moves include exiting non-core markets, acquiring KL1333, and preparing for new product launches in Europe and Japan.
-
Q3 2025 saw 30% revenue growth and a quadrupled operating profit, driven by Ruconest and Joenja. Full-year guidance was raised, with strong cash flow and disciplined capital allocation supporting pipeline and international expansion.
-
Significant transformation has led to strong double-digit growth for both commercial assets and a robust pipeline, with Joenja and KL1333 positioned as potential billion-dollar programs. Near-term catalysts include label expansions, new patient classifications, and geographic launches, supporting raised revenue guidance and a self-funded growth strategy.
-
Q2 2025 saw 26% revenue growth and a swing to operating profit, driven by RUCONEST and Joenja. Guidance for 2025 was raised, with strong cash flow and pipeline progress, including regulatory filings and a major acquisition. Competitive and FX risks remain.
-
A novel high-throughput study functionally classified thousands of APDS gene variants, uncovering many new gain-of-function mutations and revealing a much higher disease prevalence than previously recognized. These findings will enable rapid reclassification of VUS, expanding patient access to targeted therapy.
-
The meeting highlighted strong 2024 financial growth, strategic pipeline expansion, and robust governance improvements. Shareholders approved all proposals, including new board appointments and auditor reappointment, while management addressed internal control and pricing risks.
-
Strong Q1 growth was driven by Ruconest and Joenja, with the latter poised for further expansion through new indications, geographic launches, and label extensions. The company is self-funding its pipeline, including the newly acquired KL1333, and is preparing for potential supply chain risks.
-
Q1 2025 saw 42% revenue growth, led by RUCONEST and Joenja, with improved margins and a narrowed operating loss. Full-year guidance was raised, G&A costs are being cut, and the pipeline advanced with the Abliva acquisition and new studies.
-
2024 saw strong revenue growth, driven by RUCONEST and Joenja, with Joenja poised for further expansion through VUS reclassification, pediatric label extension, and global launches. The pipeline, including KL1333 for mitochondrial disease, supports long-term rare disease leadership.
-
The conference highlighted robust revenue growth from RUCONEST and Joenja, strategic expansion through the Abliva acquisition, and a strong pipeline targeting rare diseases. Ongoing regulatory submissions and pediatric studies aim to broaden market reach and future revenue streams.
Fiscal Year 2024
-
2024 revenue grew 21% to $297M, led by RUCONEST and Joenja, with strong Q4 results and positive cash flow. 2025 guidance targets $315–$335M revenue, driven by continued RUCONEST growth, Joenja expansion, and new pipeline assets from the Abliva acquisition.
-
The acquisition of Abliva AB and KL1333 strengthens the rare disease pipeline with a de-risked, late-stage asset targeting primary mitochondrial disease. The deal is fully funded, leverages existing infrastructure, and is backed by key stakeholders, with KL1333 expected to drive growth and reach the market before other pipeline products.
-
The conference highlighted strong revenue growth from Ruconest and Joenja, with Joenja's patient pool expected to double through genetic testing and pediatric expansion. Global market entry and new indications are set to drive further growth, while financial guidance remains robust.
-
Q3 revenues rose 12% year-over-year, led by Ruconest and Joenja, with strong cash flow and global expansion. Guidance remains unchanged, with growth expected from new indications, pediatric expansion, and international launches. Net loss was $1M due to FX impacts.
-
A rare disease biopharma is driving growth with Ruconest and Joenja, expanding globally and advancing new indications. Financial guidance projects $280–$295M in 2024 revenue, with stable expenses and strong balance sheet supporting further in-licensing and acquisitions.
-
Ruconest continues to grow in the U.S. by serving a unique patient subset, while Joenja's APDS launch is expanding rapidly with strong sales and a growing patient pool. Pipeline expansion into new indications and geographies, along with active business development, positions the company for significant long-term growth.
-
Q2 2024 revenue grew 35% year-over-year, led by Ruconest and Joenja, with strong patient and prescriber growth. 2024 guidance is reaffirmed, with Joenja’s addressable market set to expand via VUS resolution and pediatric label, and ex-U.S. launches expected in 2025–2026.
-
The company is driving growth through Ruconest and Joenja, with expanding indications, global regulatory submissions, and a focus on rare diseases. Joenja’s patient base is set to grow as genetic validation progresses, and new markets and indications are expected to fuel revenue from 2025 onward.